Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our opinions or reviews. Learn how we make money.
Laboratory Corporation of America Holdings is a diagnostics & research business based in the US. Laboratory Corporation of America shares (LH) are listed on the NYSE and all prices are listed in US Dollars. Laboratory Corporation of America employs 65,000 staff and has a trailing 12-month revenue of around USD$11.5 billion.
|Latest market close||USD$184.33|
|52-week range||USD$98.02 - USD$201.88|
|50-day moving average||USD$183.1962|
|200-day moving average||USD$167.3315|
|Wall St. target price||USD$228.47|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$3.709|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-09-11)||N/A|
|1 month (2020-08-18)||N/A|
|3 months (2020-06-18)||N/A|
|6 months (2020-03-18)||N/A|
|1 year (2019-09-18)||N/A|
|2 years (2018-09-18)||N/A|
|3 years (2017-09-18)||N/A|
|5 years (2015-09-18)||N/A|
Valuing Laboratory Corporation of America stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Laboratory Corporation of America's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Laboratory Corporation of America's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 50x. In other words, Laboratory Corporation of America shares trade at around 50x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Laboratory Corporation of America's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.161. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Laboratory Corporation of America's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Laboratory Corporation of America's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$1.8 billion.
The EBITDA is a measure of a Laboratory Corporation of America's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||USD$11.5 billion|
|Operating margin TTM||11.54%|
|Gross profit TTM||USD$3.3 billion|
|Return on assets TTM||4.65%|
|Return on equity TTM||4.99%|
|Market capitalisation||USD$17.8 billion|
TTM: trailing 12 months
There are currently 1.4 million Laboratory Corporation of America shares held short by investors – that's known as Laboratory Corporation of America's "short interest". This figure is 1.3% down from 1.4 million last month.
There are a few different ways that this level of interest in shorting Laboratory Corporation of America shares can be evaluated.
Laboratory Corporation of America's "short interest ratio" (SIR) is the quantity of Laboratory Corporation of America shares currently shorted divided by the average quantity of Laboratory Corporation of America shares traded daily (recently around 804163.06818182). Laboratory Corporation of America's SIR currently stands at 1.76. In other words for every 100,000 Laboratory Corporation of America shares traded daily on the market, roughly 1760 shares are currently held short.
However Laboratory Corporation of America's short interest can also be evaluated against the total number of Laboratory Corporation of America shares, or, against the total number of tradable Laboratory Corporation of America shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Laboratory Corporation of America's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Laboratory Corporation of America shares in existence, roughly 10 shares are currently held short) or 0.0165% of the tradable shares (for every 100,000 tradable Laboratory Corporation of America shares, roughly 17 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Laboratory Corporation of America.
Find out more about how you can short Laboratory Corporation of America stock.
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Laboratory Corporation of America.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Total ESG risk: 19.26
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Laboratory Corporation of America's overall score of 19.26 (as at 08/01/2020) is excellent – landing it in it in the 13rd percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Laboratory Corporation of America is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Environmental score: 4.17/100
Laboratory Corporation of America's environmental score of 4.17 puts it squarely in the 7th percentile of companies rated in the same sector. This could suggest that Laboratory Corporation of America is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Social score: 11.07/100
Laboratory Corporation of America's social score of 11.07 puts it squarely in the 7th percentile of companies rated in the same sector. This could suggest that Laboratory Corporation of America is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Governance score: 13.02/100
Laboratory Corporation of America's governance score puts it squarely in the 7th percentile of companies rated in the same sector. That could suggest that Laboratory Corporation of America is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Controversy score: 2/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Laboratory Corporation of America scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that Laboratory Corporation of America has, for the most part, managed to keep its nose clean.
|Total ESG score||19.26|
|Total ESG percentile||12.92|
|Environmental score percentile||7|
|Social score percentile||7|
|Governance score percentile||7|
|Level of controversy||2|
We're not expecting Laboratory Corporation of America to pay a dividend over the next 12 months.
Laboratory Corporation of America's shares were split on a 2:1 basis on 13 May 2002. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Laboratory Corporation of America shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Laboratory Corporation of America shares which in turn could have impacted Laboratory Corporation of America's share price.
Over the last 12 months, Laboratory Corporation of America's shares have ranged in value from as little as $98.02 up to $201.88. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Laboratory Corporation of America's is 1.3222. This would suggest that Laboratory Corporation of America's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Laboratory Corporation of America Holdings operates as an independent clinical laboratory company worldwide. It operates in two segments, LabCorp Diagnostics (LCD) and Covance Drug Development. It offers various clinical laboratory tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, Pap tests, hemoglobin A1C and vitamin D products, prostate-specific antigens, tests for sexually-transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests. The company also provides testing services in the areas of women's health, allergy, diagnostic genetics, cardiovascular and infectious disease, endocrinology, oncology, coagulation, pharmacogenetics, toxicology, and medical drug monitoring; and esoteric testing, cancer diagnostics, and other procedures. In addition, it provides a suite of applications to enable patients, healthcare providers, health systems, accountable care organizations, and insurers with access to LCD's data and services, as well as billing for laboratory services. Further, it offers end-to-end drug development, medical device, and diagnostic development solutions from research to clinical development and commercial market access. The company primarily serves managed care organizations, biopharmaceutical companies, physicians and other healthcare providers, hospitals and health systems, governmental agencies, employers, patients and consumers, contract research organizations, academic institutions, and independent clinical laboratories. Laboratory Corporation of America Holdings has collaborations with the Boston University, Columbia University, Duke University, Johns Hopkins University, The Mount Sinai Hospital, the University of Tennessee, Yale University, and QIAGEN N.V; and Ciox Health for the creation of COVID-19 patient data registry in the United States. The company was founded in 1971 and is headquartered in Burlington, North Carolina.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.